Reports
Sale
Ophthalmoplegia Market Size, Trends, Analysis, Forecast: By Type: External Ophthalmoplegia, Internuclear Opthalmoplegia; By Treatment Type: Surgery, Drug Treatment, Others; By End User: Hospital and Clinics, Ambulatory Clinics, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Ophthalmoplegia Market Outlook
The ophthalmoplegia market size was valued at USD 1032.7 million in 2023, driven by the increasing advancements in healthcare and pharmaceutical industry across the 7 major markets. The market is expected to grow at a CAGR of 8.3% during the forecast period of 2024-2032, with the value likely to reach USD 2130.2 million by 2032.
Ophthalmoplegia: Introduction
Ophthalmoplegia is the weakness of the eye muscles, affecting one or more than one of the six muscles holding the eye in place and controlling its movement. It can be further segmented into chronic progressive external ophthalmoplegia and internal ophthalmoplegia. People suffering from ophthalmoplegia may have blurred or double vision, and even misaligned eyes in some cases. It is mostly diagnosed through MRI or CT scans.
Ophthalmoplegia Market Analysis
The incidence of ophthalmoplegia is slightly higher in people affected with diabetes. Since the prevalence of diabetes is growing due to the changes in modern lifestyles and unhealthy dietary practices, the ophthalmoplegia market demand has also observed an upswing. Along with diabetes, patients affected by multiple sclerosis or Graves’ disease are also at a risk of developing the condition.
With the rising preference for minimally invasive surgical interventions, silicone sling procedure is commonly performed as an ophthalmoplegia treatment. This procedure is used to treat drooping eyelids, a critical symptom of the disease. It is performed with the help of a Seiff silicone suspension and the silicone is guided in the muscle through a stab incision. This procedure offers multiple advantages like early recovery, less surgical time, and no multiple incisions when compared to other methods.
Apart from surgical interventions and drugs like tetracycline, corticosteroid treatment, and botulinum toxin, vitamins are also used quite frequently. However, adopting traditional Chinese medicine as a complementary and alternative method, acupuncture is also being investigated as a potential therapeutic method. With a vision to cater to a diverse set of patients, scientists are looking into various approaches, which are poised to boost the ophthalmoplegia market value in the forecast period.
Ophthalmoplegia Market Segmentation
Market Breakup by Type
- External Ophthalmoplegia
- Internuclear Opthalmoplegia
Market Breakup by Treatment Type
- Surgery
- Drug Treatment
- Others
Market Breakup by End User
- Hospital and Clinics
- Ambulatory Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Ophthalmoplegia Market Overview
North America has been dominating the ophthalmoplegia market share owing to factors like a well-developed healthcare infrastructure and the increased presence of prominent pharmaceutical companies. In addition, companies have been expanding their product portfolios for better patient outcomes.
Europe is another major market with a high emphasis on offering better healthcare solutions to patients. With substantial geriatric population, the region may experience more ophthalmoplegia cases in upcoming years. Therefore, there has been significant focus on developing innovative and highly effective treatment alternatives. The rising technical advancements that incorporate artificial intelligence and machine learning into drug development are some of the critical trends shaping the market value in the region.
The Asia Pacific is projected to witness significant ophthalmoplegia market growth which can be attributed to rising healthcare investments from the native governments as well as foreign companies. Along with improving the healthcare infrastructure, several influential pharmaceutical companies are setting up new research labs and clinics to put the easily available resources in the area to use.
Ophthalmoplegia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- Bausch Health
- Johnson & Johnson Services, Inc.
- Medline Industries
- Santen Pharmaceutical Co.
- Novartis AG
- Abbott
- Essilor
- Astellas Pharma Inc.
- Enzon Pharmaceuticals
- Amritt, Inc.
- NIDEK CO.
- Carl Zeiss AG
- Santen Pharmaceutical Co.
- Medline Industries
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ophthalmoplegia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ophthalmoplegia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3.1 Germany Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3.2 France Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3.3 Italy Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3.4 Spain Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Ophthalmoplegia Epidemiology Forecast (2017-2032)
5.4 Japan Ophthalmoplegia Epidemiology Forecast (2017-2032)
6 Ophthalmoplegia Market Overview – 7MM
6.1 Ophthalmoplegia Market Historical Value (2017-2023)
6.2 Ophthalmoplegia Market Forecast Value (2024-2032)
7 Ophthalmoplegia Market Landscape – 7MM
7.1 Ophthalmoplegia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ophthalmoplegia Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Treatment Type
8 Ophthalmoplegia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ophthalmoplegia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ophthalmoplegia Market Segmentation – 7MM
11.1 Ophthalmoplegia Market by Type
11.1.1 Market Overview
11.1.2 External Ophthalmoplegia
11.1.3 Internuclear Opthalmoplegia
11.2 Ophthalmoplegia Market by Treatment Type
11.2.1 Market Overview
11.2.2 Surgery
11.2.3 Drug Treatment
11.2.4 Others
11.3 Ophthalmoplegia Market by End User
11.3.1 Market Overview
11.3.2 Hospital and Clinics
11.3.3 Ambulatory Clinics
11.3.4 Others
11.4 Ophthalmoplegia Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Ophthalmoplegia Market
12.1 Ophthalmoplegia Market Historical Value (2017-2023)
12.2 Ophthalmoplegia Market Forecast Value (2024-2032)
12.3 Ophthalmoplegia Market by Disease Type
12.4 Ophthalmoplegia Market by Treatment Type
13 EU-4 and United Kingdom Ophthalmoplegia Market
13.1 Ophthalmoplegia Market Historical Value (2017-2023)
13.2 Ophthalmoplegia Market Forecast Value (2024-2032)
13.3 Germany Ophthalmoplegia Market Overview
13.3.1 Ophthalmoplegia Market by Disease Type
13.3.2 Ophthalmoplegia Market by Treatment Type
13.4 France Ophthalmoplegia Market Overview
13.4.1 Ophthalmoplegia Market by Disease Type
13.4.2 Ophthalmoplegia Market by Treatment Type
13.5 Italy Ophthalmoplegia Market Overview
13.5.1 Ophthalmoplegia Market by Disease Type
13.5.2 Ophthalmoplegia Market by Treatment Type
13.6 Spain Ophthalmoplegia Market Overview
13.6.1 Ophthalmoplegia Market by Disease Type
13.6.2 Ophthalmoplegia Market by Treatment Type
13.7 United Kingdom Ophthalmoplegia Market Overview
13.7.1 Ophthalmoplegia Market by Disease Type
13.7.2 Ophthalmoplegia Market by Treatment Type
14 Japan Ophthalmoplegia Market
14.1 Ophthalmoplegia Market Historical Value (2017-2023)
14.2 Ophthalmoplegia Market Forecast Value (2024-2032)
14.3 Ophthalmoplegia Market by Disease Type
14.4 Ophthalmoplegia Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 F. Hoffmann-La Roche Ltd
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bausch Health
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Johnson & Johnson Services, Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Medline Industries
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Santen Pharmaceutical Co.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Novartis AG
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Abbott
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Essilor
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Astellas Pharma Inc.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Enzon Pharmaceuticals
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Amritt, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 NIDEK CO.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Carl Zeiss AG
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Santen Pharmaceutical Co.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Ophthalmoplegia Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1032.7 million in 2023, driven by the growing technical advances in medical and pharmaceutical industry.
The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to reach a market value of USD 2130.2 million by 2032.
The market is driven by the rising prevalence of diabetes and multiple sclerosis, which can be considered as a major risk to be affected from ophthalmoplegia.
The major market trend revolves around the increasing adoption of traditional medicine alternatives like acupuncture to treat a diverse set of symptoms affecting the patients. The Asia-Pacific region is poised to witness substantial market growth in the forecast period.
Based on treatment types, the market is divided into surgery, drug treatment and others.
Major end users include hospitals, clinics, ambulatory clinics, and others.
Based on types, ophthalmoplegia can be divided into external and internuclear ophthalmoplegia.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are F. Hoffmann-La Roche Ltd, Bausch Health, Johnson & Johnson Services, Inc., Medline Industries, Santen Pharmaceutical Co., Novartis AG, Abbott, Essilor, Astellas Pharma Inc., Amritt, Inc., NIDEK CO., Carl Zeiss AG, Santen Pharmaceutical Co., and Enzon Pharmaceuticals.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER